15-min delayed · Sep 9, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 10 firms covering BioCryst Pharmaceuticals Inc, 8 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. The target range is very wide, $9.00 to $32.00 (about 3.6x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $21.60 sits 145% above the current $8.80. The rating mix has stayed broadly stable, with Buy-side ratings easing from 9 to 8 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.13 next quarter toward $0.94 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 ratings
Strong Buy
Strong Buy00%
Buy880%
Hold220%
Sell00%
Strong Sell00%
Based on 10 analysts giving stock ratings to BioCryst Pharmaceuticals Inc.
As of Sep, 8 of 10 firms rate BCRX a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BCRX EPS & revenue forecast
EPS · NEXT QUARTER
$0.13
Range $0.10 – $0.15 · 2 analysts · -40% YoY
Next period, 2 analysts expect BioCryst Pharmaceuticals Inc to earn $0.13 a share (range $0.10 – $0.15), versus $0.21 a year earlier. Full-year consensus is $0.74, growing to $0.94 the year after.
REVENUE · NEXT QUARTER
$169.4M
Range $163.4M – $173.7M · 2 analysts · -58% YoY
Revenue is expected to reach $169.4M (range $163.4M – $173.7M), -58.3% year-over-year. Full-year consensus is $702.2M, rising to $737.3M next year.
Top analysts covering BioCryst Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BCRX.
#1
Jonathan Wolleben
JMP Securities · Rank #29
Buy
$28.00+218.2% to target
Overall win rate
47%
+ Follow
#2
Andrew Fein
HC Wainwright & Co. · Rank #55
Buy
$32.00+263.6% to target
Overall win rate
46%
+ Follow
#3
Jessica Fye
JP Morgan · Rank #71
Hold
$12.00+36.4% to target
Overall win rate
53%
+ Follow
#4
Laura Chico
Wedbush · Rank #74
Buy
$20.00+127.3% to target
Overall win rate
44%
+ Follow
#5
Serge Belanger
Needham · Rank #105
Buy
$16.00+81.8% to target
Overall win rate
48%
+ Follow
BCRX stock forecast FAQ
What is BCRX's average 12-month price target?+
The 10 analysts with a live target average $21.60 for BioCryst Pharmaceuticals Inc over the next 12 months, ranging from a $32.00 high to a $9.00 low.
Is BCRX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 10 analyst ratings, 8 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for BCRX?+
The Street-high target is $32.00 (HC Wainwright & Co.), and the Street-low is $9.00 (Barclays). The average of all 10 active targets is $21.60.
How many Wall Street analysts cover BCRX?+
10 analysts have an active rating on BioCryst Pharmaceuticals Inc, and 10 firms carry a live 12-month price target.
Who is the most accurate analyst covering BCRX?+
Among analysts who currently cover BCRX, Jonathan Wolleben of JMP Securities has the strongest overall Quantellect track record (Rank #29). Their current call is Buy with a $28.00 target.
What is BioCryst Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $0.13 per share (range $0.10 – $0.15) across 2 analysts. Full-year EPS is projected at $0.74, rising to $0.94 the following year.
How much revenue is BioCryst Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $169.4M (range $163.4M – $173.7M). Full-year revenue is projected at $702.2M, growing to $737.3M next year.
Have analysts been upgrading or downgrading BCRX lately?+
As of Sep, 8 of 10 firms rate BCRX a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BCRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
